KNM books revenue and chases 200,000 sign-ups

|

Published 14-APR-2016 12:19 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

KNeoMedia is now providing a special needs version of its KNeoWORLD software to 600 students in New York – but is eyeing up 200,000 licenses.

The ASX-listed ‘edutainment’ play has told its shareholders that it has signed up another 400 special students onto a specially designed KNeoWORLD platform – taking the total to 600.

It said that it received $50 per license (or student) as part of the latest sign-up, meaning that it will book $20,000 in revenue.

Aside from the immediate revenue boost, KNM said that the deal had afforded it greater visibility in the special needs system of New York, where there are an estimated 200,000 special needs students.

“We are experiencing considerable visibility across the New York public school system, and now that we have a special education version of KNeoWORLD in four public schools in Bronx and Harlem, more will certainly follow,” KNM chief executive James Kellett said.

“This is significant validation and pleasing revenue diversity in what is a large and very lucrative market.”

The funding for the programs came from philanthropic funding, with corporate, government, and private philanthropic funds making money available for students to access specially designed special needs learning platforms – such as the one KNM has created.

In other KNM news, it said that it would be in a position to update the market on new language versions of its software “shortly”.

About KNM

KNeoMedia is an online games publishing company that delivers world-class edutainment (education and entertainment) games to global educational and consumer markets.

The edutainment industry is currently a $1.5BN industry and is set to grow to $2.3BN in the next two years.

KNM sells its games on a micro-subscription and Apps basis through the KNeoworld.com games portal, App stores and via distribution agreements and education departments.

Primary-aged students (aged between 5 and 13) can play their way through games that are subtly infused with high level educational content in the areas of numeracy, literacy, science and arts.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X